The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Familial Cold Urticaria
About this trial
This is an interventional treatment trial for Familial Cold Urticaria focused on measuring Familial Cold Urticaria, Kineret (anakinra), Interleukin 1 beta, C-Reactive Protein, Serum Amyloid A protein
Eligibility Criteria
Inclusion Criteria: Must be 18 years of age or older at the time of enrollment; may be male or female Must be previously diagnosed with Familial Cold Urticaria (FCU) Must react with at least one of the symptoms of FCU in the summer months at least four times per week sufficiently to interfere with ordinary daily activities or inhibit normal life enjoyment. Women must be willing to have a pregnancy test and if necessary, use contraceptive measures. Exclusion Criteria: Receiving any systemic medications/treatments that could affect FCU. Pregnancy, nursing or planning pregnancy, or, have recently been pregnant to less than three months development and with a history of serious birth defect. Have had any previous treatment with Kineret (anakinra) or any therapeutic agent targeted at IL-1 blockade. Have used any investigational drug within the previous 1 month or five times the half life of the investigational agent, whichever is longer, or 3 months for any biologic of unknown half life. Have received any systemic medication or treatments that could affect the symptoms of FCU such as antihistamines, corticosteroid drugs, NSAIDS, anabolic medications or Ketotifen within 2 weeks of the baseline visit. Have any known malignancy or have a history of malignancy within the previous five years (with the exception of basal or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence).
Sites / Locations
- Queen Elizabeth Health Sciences Centre